Unfortunately, the recombinant human IL15 protein used in clinical trials, to treat cancer patients, undergoes a rapid renal clearance and has a short plasma half‐life which diminishes its anti‐tumour effects (Chertova et al, 2013). Here, IL15 is linked to neoplasm.